CellCentric raises £19million for clinical testing of prostate cancer drug
Drug could help more than 80,000 patients a year - and might help fight haematological, bladder and lung cancers
CellCentric has raised $26million (£19.2million) in private financing to fund clinical testing of a drug candidate for late-stage prostate cancer patients.
The small molecule inhibitor, CCS1477, could help more than 80,000 patients a year and also has the potential to tackle haematological, bladder and small cell lung cancers.
The funding for the Chesterford Research Park firm will take the drug candidate to phase IIb and comes from existing investor Morningside Venture Investments, which also announced its £11million injection into PhoreMost on the same day (Tuesday May 15).
Dr Will West, chairman and CEO of CellCentric, said: “There is a large and growing population of late-stage prostate cancer patients who have inherent or acquired resistance to current second-line anti-androgen therapies.
“CCS1477 has shown promise in addressing this. It is positioned after or in combination with second generation anti-androgen drugs such as abiraterone, enzalutamide and apalutamide.”
Dr Jason Dinges, CellCentric board director and Morningside representative, added: “Oncology product development is highly competitive. There are few genuine first-in-class new drug opportunities which have a large but specific patient population to treat. Morningside is also encouraged by new data demonstrating that p300/CBP inhibition has significant potential for other areas beyond prostate cancer.”
CellCentric’s clinical programme in prostate cancer will start early this summer at the Royal Marsden Hospital before expanding nationally and then to the US.
CCS1477’s progress has also been aided by a BioMedical Catalyst awards from Innovate UK and the Prostate Cancer Foundation.
CellCentric is a privately held business, with Morningside Venture Investments as its lead investor, and has active collaborations with research centres in Europe and the US.